Details

Autor(en) / Beteiligte

• Santos-García, Diego
• de Deus Fonticoba, T.
• Suárez Castro, E.
• Aneiros Díaz, A.
• Paz González, J. M.
• Feal Panceiras, M. J.
• García Sancho, C.
• Jesús, S.
• Mir, P.
• Aguilar, M.
• Pastor, P.
• Hernández Vara, J.
• de Fábregues-Boixar, O.
• Puente, V.
• Crespo Cuevas, A.
• González-Aramburu, I.
• Infante, J.
• Carrillo Padilla, F.
• Pueyo, M.
• Escalante, S.
• Bernardo, N.
• Solano, B.
• Cots Foraster, A.
• Martinez-Martin, P.

Titel

High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

Ist Teil von

• Journal of Neural Transmission, 2019-12, Vol.126 (12), p.1599-1608

Ort / Verlag

Vienna: Springer Vienna

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• C-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group ( n  = 225; 61.8 ± 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group ( n  = 65; 60.3 ± 6.1 years old, 56.9% males) ( p  < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 ± 0.52 vs 0.16 ± 0.21 vs 0.21 ± 0.22; p  = 0.04). Significant differences were also observed between patients with vs without FOG ( p  = 0.001) but not between patients and controls ( p  = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105–17.275; p  = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113–7.943; p  = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005–1.029; p  = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.